InterAx Overview

  • Status
  • Private

  • Employees
  • 17

Employees
  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 11

InterAx General Information

Description

Developer of a drug discovery platform created to reduce the time and costs for the discovery and development of new drugs for a wide array of human diseases. The company combines artificial intelligence, mathematical models of signaling pathways, cellular assays, and computational chemistry enabling it to cover signaling response characterization and optimization where it uniquely takes into account cellular background effects (system bias) as well as experimental assays amplification effects and temporal effects (observation bias) with proprietary mathematical models.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
  • Park Innovaare
  • 5234 Villigen
  • Switzerland

InterAx Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InterAx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 01-Nov-2022 00.000 Completed Pre-Clinical Trials
7. Grant 25-Nov-2019 00.000 00.000 Completed Pre-Clinical Trials
6. Accelerator/Incubator 11-Oct-2019 00.000 00.000 Completed Pre-Clinical Trials
5. Seed Round 15-Jan-2019 00.000 00.000 000.00 Completed Pre-Clinical Trials
4. Seed Round 23-Dec-2016 00000 Completed Startup
3. Grant 21-Oct-2016 000.00 00000 Completed Startup
2. Accelerator/Incubator 01-Jan-2016 $130K $130K Completed Startup
1. Grant 01-Aug-2014 $167K Completed Startup
To view InterAx’s complete valuation and funding history, request access »

InterAx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 00.00 00.00 00 00.00 00.000
To view InterAx’s complete cap table history, request access »

InterAx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform created to reduce the time and costs for the discovery and development of new dru
Discovery Tools (Healthcare)
Villigen, Switzerland
17 As of 2022
00.000
0000000000 0 00.000

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labo
000000000 00000 (000
Oxford, United Kingdom
000 As of 0000
00000
000000000 00000

000000

t, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000 000000000
San Diego, CA
000 As of 0000
00000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InterAx Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exscientia Formerly VC-backed Oxford, United Kingdom 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 00000000
00000 000000000000 Formerly VC-backed Cambridge, United Kingdom 00 00000 000000&0 00000
00000000 Venture Capital-Backed San Francisco, CA 00 00000 0000000000 00000
000000 00000000000 Venture Capital-Backed Boston, MA 00 00000 0000000000 0 00000
You’re viewing 5 of 41 competitors. Get the full list »

InterAx Patents

InterAx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3878447-A1 Beta adrenergic receptor antagonists Inactive 11-Mar-2020 0000000000 0
US-20220106382-A1 Beta-arrestin mutants Pending 22-Jan-2019 0000000000
JP-7216216-B2 Beta-arrestin mutant Active 22-Jan-2019 0000000000 0
JP-2022518549-A Beta-arrestin mutant Active 22-Jan-2019 0000000000 0
CA-3127255-A1 Beta-arrestin mutants Pending 22-Jan-2019 C07K14/723
To view InterAx’s complete patent history, request access »

InterAx Executive Team (8)

Name Title Board Seat Contact Info
Christopher Prior Chief Executive Officer
Luca Zenone Co-Founder, Chief Operating Officer, Chief Financial Officer and Board Member
Gebhard Schertler Co-Founder & Head of Scientific Advisory Board
Mirjam Zimmermann Ph.D Head of Research
You’re viewing 4 of 8 executive team members. Get the full list »

InterAx Board Members (5)

Name Representing Role Since
Aurélien Rizk Ph.D InterAx Co-Founder & Board Member 000 0000
Bettina Ernst Ph.D Bernina BioInvest Board Member 000 0000
Jens Gobrecht Self Chairman 000 0000
Yiannis Monovoukas Ph.D Falcon III Ventures Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

InterAx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InterAx Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Convergence Partners (Switzerland) Venture Capital Minority 000 0000 000000 0
Plug and Play Tech Center Accelerator/Incubator Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
EIC Accelerator Accelerator/Incubator Minority 000 0000 000000 0
Bernina BioInvest Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »